- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07941843
Lactoferrin Supplementation for FOLFOX-Related Toxicities in Colorectal Cancer (LF-FOLFOX)
The Probability of a Protective Effect of Lactoferrin on FOLFOX-Related Toxicities in Colorectal Cancer
This randomized controlled clinical trial aims to investigate the potential protective effects of oral lactoferrin supplementation against chemotherapy-related toxicities in patients with colorectal cancer receiving the FOLFOX regimen.
A total of 44 eligible adult patients will be randomly allocated into two parallel groups (22 patients per group). The control group will receive standard FOLFOX chemotherapy, while the intervention group will receive standard FOLFOX chemotherapy plus oral lactoferrin (Pravotin) at a dose of 100 mg twice daily, starting from the first chemotherapy cycle and continuing throughout the planned chemotherapy course.
The study will evaluate peripheral neuropathy, gastrointestinal and hematological toxicities, oxidative stress and neuroprotective biomarkers.
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
Colorectal cancer is commonly treated with oxaliplatin-based chemotherapy regimens such as FOLFOX, which combines oxaliplatin, 5-fluorouracil, and leucovorin. Despite its therapeutic effectiveness, FOLFOX is associated with peripheral neuropathy, gastrointestinal toxicity, hematological abnormalities, and impaired quality of life.
Lactoferrin is an iron-binding glycoprotein with antioxidant, anti-inflammatory, immunomodulatory, and potential neuroprotective properties. These biological activities may help mitigate chemotherapy-induced toxicities.
This study will investigate the potential protective effects of lactoferrin supplementation in 44 patients with histologically confirmed colorectal cancer who are scheduled to receive at least six cycles of FOLFOX chemotherapy at Damanhour Oncology Center.
Eligible participants will be randomly assigned in a 1:1 ratio to receive either standard FOLFOX chemotherapy alone or standard FOLFOX chemotherapy combined with oral lactoferrin 100 mg twice daily.
Participants will undergo clinical evaluations, laboratory monitoring, and assessment of chemotherapy-related adverse events. Laboratory investigations will include complete blood count, kidney and liver function tests, and serum biomarkers including nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and malondialdehyde (MDA).
Clinical assessments and laboratory investigations will be conducted during chemotherapy, with final assessments at the completion of the planned chemotherapy course.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Toka M El-Banna, Clinical pharmacy TA
- Número de teléfono: 00201018546392
- Correo electrónico: tokaelbanna@gmail.com
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Adult patients aged 18 years or older with histologically confirmed colorectal cancer.
- Patients scheduled to receive at least six cycles of FOLFOX chemotherapy.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
Exclusion Criteria:
- Pre-existing peripheral neuropathy of grade 1 or higher.
- Hereditary neuromuscular disorders.
- Advanced liver disease, defined as liver enzymes greater than three times the upper limit of normal or established cirrhosis.
- Chronic kidney disease with an estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73 m².
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Cuidados de apoyo
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: Standard FOLFOX Chemotherapy
Participants assigned to the control group will receive standard FOLFOX chemotherapy consisting of oxaliplatin, 5-fluorouracil, and leucovorin according to the routine oncology treatment protocol. |
Standard FOLFOX chemotherapy consisting of oxaliplatin, 5-fluorouracil, and leucovorin, administered according to the treating oncology center's standard protocol. |
|
Experimental: FOLFOX Plus Lactoferrin
Participants assigned to the intervention group will receive standard FOLFOX chemotherapy plus oral lactoferrin supplementation (Pravotin) at a dose of 100 mg twice daily, initiated at the first chemotherapy cycle and continued throughout the planned chemotherapy course. |
Standard FOLFOX chemotherapy consisting of oxaliplatin, 5-fluorouracil, and leucovorin, administered according to the treating oncology center's standard protocol. Oral lactoferrin supplementation (Lactomash), administered at a dose of 100 mg twice daily (total daily dose: 200 mg), starting from the first FOLFOX chemotherapy cycle and continuing throughout the planned chemotherapy course. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidence of Oxaliplatin-Induced Peripheral Neuropathy
Periodo de tiempo: From baseline before initiation of FOLFOX therapy to 3 months after initiation of FOLFOX therapy.
|
Proportion of participants developing peripheral neuropathy during FOLFOX chemotherapy, assessed and graded according to biomarkers. |
From baseline before initiation of FOLFOX therapy to 3 months after initiation of FOLFOX therapy.
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Publicaciones Generales
- - Macciò A, et al. The Oncologist. 2010
- Lesser GJ, Irby MB, Taylor RC, Snavely A, Case D, Wang A, Dietrich A, Duncan S. Lactoferrin supplementation for taste and smell abnormalities among patients receiving cancer chemotherapy. Support Care Cancer. 2022 Mar;30(3):2017-2025. doi: 10.1007/s00520-021-06609-8. Epub 2021 Oct 13.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Neoplasias por sitio
- Neoplasias
- Enfermedades intestinales
- Neoplasias Gastrointestinales
- Neoplasias del Sistema Digestivo
- Enfermedades del Sistema Digestivo
- Enfermedades Gastrointestinales
- Neoplasias Intestinales
- Enfermedades Rectales
- Enfermedades del Colon
- Neoplasias colorrectales
- Aminoácidos, péptidos y proteínas
- Proteínas
- Carbohidratos
- Hidrolasas
- Enzimas
- Enzimas y coenzimas
- Globulinas
- Glicoproteínas
- Glucoconjugados
- Endopeptidasas
- Hidrolasas peptídicas
- Serina endopeptidasas
- Serina proteasas
- Proteínas dietéticas
- Proteínas de la leche
- Proteínas animales, dieta
- Proteínas portadoras
- Transferins
- Proteínas de unión a hierro
- Lactoglobulinas
- Proteínas de suero
- Metaloproteínas
- Lactoferrina
- Protocolo de Folfox
Otros números de identificación del estudio
- LF-FOLFOX-CRC-001
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Individual participant data (IPD) will not be shared.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .